Financial
FY2025/26 revenue SEK 16.72bn (-7.2%); operating margin 1.4%; net loss SEK 517.0m.
EBIT hit by impairments and restructuring; adjusted EBIT SEK 2.05bn; net debt SEK 3.19bn.
Elekta
HQ Sweden · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Fair
Customer rating
No reviews yet
Financial health
Band: FairListed: EKTA-B.ST
FY2025/26 revenue SEK 16.72bn (-7.2%); operating margin 1.4%; net loss SEK 517.0m.
EBIT hit by impairments and restructuring; adjusted EBIT SEK 2.05bn; net debt SEK 3.19bn.
Source: official results release · Year ended 2026-04-30 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025/26 | SEK 16.7bn | -7.2% | SEK 234m | -SEK 517m | Elekta |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
No adverse media involving Elekta found in HSH's search of the last 24 months.
Cyber & information governance
No confirmed data breaches, cyber incidents or regulator action involving Elekta found in HSH's search of the last 24 months. Unverified claims on ransomware leak-site trackers are not included. NHS DSPT status not yet checked.
Regulatory & clinical safety
Apr 2026: Elekta began a US FDA Class 2 recall of its Advanced Gynecological brachytherapy applicator after reports the intrauterine tube tip can detach. In Sep 2025 it also recalled Leksell Vantage stereotactic frames over paint flakes, which it said had not been seen clinically.
Contract performance
Dec 2025: Elekta was named, with Varian and Accuray, as a supplier of the 28 new radiotherapy linear accelerators NHS Supply Chain is buying for 2025/26 through its framework, which reported £21.8m of savings.
Competitors
No competitors linked yet.